Skip to content

Corporate Sponsored Funding

PIVOT Center works with companies to thoroughly understand their R&D goals and match them to research goals of the appropriate faculty members at the University of Utah. PIVOT’s Corporate Engagement team works across all schools and units to facilitate partnerships and offer expertise on identifying opportunities that include grant funding, sponsored research and creating strategic corporate partnerships. PIVOT also provides guidance to faculty for successful stewardship. Please contact Sadhna Kohli (Director of Corporate Engagement) for more information regarding these opportunities, or if you have any questions.


Pfizer: Closing Knowledge Gaps in Moderate-to-Severe Alopecia Areata
Amount: $300,000
Deadline: May 26th, 2021

Projects that will be considered for Pfizer support should focus on increasing the knowledge and understanding of: 1) the pathophysiology of alopecia areata with specific focus on immunologic pathways, including how the pathway differs from other causes of hair loss; and 2) the epidemiology of alopecia areata, including an understanding of the risk factors; and 3) understanding the clinical manifestation of alopecia areata, including a holistic review of the burden of disease (e.g. psychosocial burden and associated autoimmune disorders).

Click here to learn more!


Pfizer: Pediatric Endocrinology Fellowship
Amount: $75,000
Deadline: June 1st, 2021

The intent is to support institutions with fellowship programs for Pediatric Endocrinologists that have a strong focus on clinical practice, research, and education to further the understanding of short stature/growth failure

Click here to learn more!


Pfizer: 2021 Growth Hormone Research
Amount: $100,000
Deadline: June 1st, 2021

Research projects that will be considered for Pfizer support will advance the medical knowledge of short stature.  Projects submitted may include:

  • Diagnostics, early treatment, new treatment paradigms
  • Clinical outcomes, quality of life, and patient reported outcomes
  • Medication adherence research
  • Translational or clinical research

Click here to learn more!


Pfizer: Quality Improvement Grants to Support the Delivery of Gene Therapies to Patients with Rare Disease
Amount: $50,000
Deadline: June 1, 2021

Projects that will be considered for Pfizer support will focus on preparing and/or optimizing multidisciplinary care teams for the integration of gene therapy into the treatment armamentarium for patients with a Rare Disease. Support is available for the development of leadership, best practices, SOP development, site readiness, support and/or training of HCPs within a multidisciplinary team environment to optimize the quality of care for patients who have/will have gene therapy in their treatment armamentarium.  

Projects that address recombinant adeno-associated virus gene therapy in Rare Disease and are therapeutic area and disease area agnostic (i.e., platform) will be prioritized. It is not our intent to support clinical research projects. Projects evaluating the efficacy of therapeutic or diagnostic agents will not be considered. 

Click here to learn more!


Pfizer: Acromegaly
Amount: $100,000
Deadline: June 1st, 2021

Projects that will be considered for Pfizer support will focus on:

  • Morbidity and mortality in Growth Hormone Excess
  • Novel strategies including Quality of Life and Patient Reported Outcomes to evaluate and treat Growth Hormone Excess
  • Early diagnosis and treatment of Growth Hormone Excess
  • Pathophysiology of Growth Hormone Excess 

Click here to learn more!


Facebook: Next-generation Data Infrastructure
Amount: $50,000
Deadline: June 2nd, 2021

Areas of interest include, but are not limited to, the following:

  1. Large scale query processing
  2. Physical layout and IO optimizations
  3. Data management and processing at a global scale
  4. Converged architectures for data wrangling, machine learning, and analytics
  5. Advances in testing and verification for storage and processing systems

Click here to learn more!


Pfizer: Addressing Social Health Needs in Chronic and Preventative Disease
Amount: $250,000
Deadline: June 2, 2021

The intent of this RFP is to encourage proposals to join a Learning and Action Network (LAN) to support the journey of health care organizations seeking to integrate social care into health care delivery in pursuit of improved health, well-being, and equity for their populations. The LAN will focus on the social care integration work of 3-5 integrated delivery networks (IDNs) in the United States, also known as health systems - organizations that own and operate a network of one or more health care facilities. Each selected IDN will set 12-month goals specific to their contexts. Participants will test social care integration strategies with their patient populations and share their results both with one another and stakeholders in their own IDNs to enhance the rate of learning and improvement. This LAN will be convened by IHI and funded by Pfizer.

Click here to learn more!


Pfizer: Burden of Community Acquired Pneumonia
Amount: $150,000
Deadline: June 9th, 2021

Studies that will be considered for Pfizer support will focus on evaluating the

burden of community acquired pneumonia, including but not limited to

pneumococcal pneumonia, as well as risk factors for and complications from

disease.

Click here to learn more!


Pfizer: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Research – U.S.
Amount: $75,000
Deadline: June 9, 2021

Projects that will be considered for Pfizer support will focus on several or one

specified area:

  • Early identification, evaluation, diagnosis, prognosis & treatment
  • Study of hereditary ATTR genotypes and phenotypes
  • Non-Val30Met genotypes
  • Val122Ile, Thr60Ala, Val30Met, and others
  • Mixed phenotypic manifestations (e.g. polyneuropathy and cardiomyopathy)
  • Use of tafamidis in the clinical setting (i.e. real-world evidence)

Click here to learn more!


Pfizer: Racial and Ethnic Disparities in the Menopause Experience
Amount: $100,000
Deadline: June 10, 2021

Projects that will be considered for Pfizer support will focus on increasing awareness and understanding among health care providers about racial and ethnic differences in patients’ menopause experiences. Closing these knowledge gaps are important to help ensure that patients receive proper diagnosis, appropriate treatment and optimal care.

Click here to learn more!


Pfizer: Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Nurse Navigator Competitive Grant Program
Amount: $75,000
Deadline: June 15, 2021

Projects that will be considered for funding will focus on supporting the development of nurse navigator programs, including training, in order to improve the quality of care for ATTR-CM patients.

Click here to learn more!


Pfizer: Management of Metabolic Risks that Drive Liver Diseases and Increase Cardiovascular Risk in NASH
Amount: $200,000
Deadline: June 15, 2021

Pfizer intent is to provide an independent grant(s) to an organization or organizations that will focus on the management of metabolic disorders’ risks that drive liver disease outcomes and increase cardiovascular risk in non-alcoholic steatohepatitis (NASH). Projects that will be considered for Pfizer support will focus on:

  • Innovative treatment approaches to reduce the risk of, slow or prevent progression to severe liver outcomes such as advanced fibrosis, cirrhosis, hepatocellular carcinoma, or liver transplant
  • Understanding the linkage of NAFLD/NASH and cardiovascular disease in patients with NASH
  • Understanding the contribution of NAFLD/NASH to overall morbidity and mortality risks

Click here to learn more!


Pfizer: Transthyretin Cardiac Amyloidosis Fellowship
Amount: $80,000
Deadline: June 15th, 2021

The intent is to support institutions with fellowship programs for Cardiologists that have a strong focus on clinical practice, research, and education to further the understanding of transthyretin cardiac amyloidosis. Grants will be available for both established and emerging Amyloid Centers of Excellence.

Click here to learn more!


Pfizer: Closing Knowledge Gaps in Osteoarthritis and Osteoarthritis Pain
Amount: $200,000
Deadline: June 18th, 2021

The intent is to support virtual and potentially live programs and other innovative digital medical education for Health Care Professionals. The focus is on Osteoarthritis and Chronic Pain associated with OA and patient-centered standard of care and management including pain and function, the biopsychosocial aspects of the disease, the complexities and challenges of care, and the future of OA/OA pain management. Programs targeted towards reviewing data at virtual or live osteoarthritis, rheumatology, pain, primary care, or other associated medical conferences, including but not limited to OARSI, EULAR, PAINWeek, AAFP, WCO, and ACR are of particular interest, as well as other meaningful education outside of congresses.

Click here to learn more!


Pfizer/NCCN: Development of Talazoparib for Prostate Cancer
Amount: $375,000
Deadline: June 21st, 2021

The intent of the RFP is to encourage organizations to submit letters of intent (LOIs) describing concepts and ideas to promote the further development of talazoparib for the treatment of prostate cancer.

Click here to learn more!


Pfizer: NSCLC Biomarker Testing
Amount: $150,000
Deadline: June 23rd, 2021

 Projects that will be considered for Pfizer support will be Quality Improvement

initiatives that analyze and improve biomarker testing practices in NSCLC.

Grant support is available to cancer centers or hospitals interested in forming

multi-disciplinary teams to analyze their own testing practices and identify

areas of improvement using Quality Improvement (QI) methodology such as

root cause analysis, Plan Do Study Act (PDSA) cycles etc.

Click here to learn more!


Pfizer: Centers for Therapeutic Innovation (CTI)
Amount:
Varies
Deadline: June 28, 2021

Pfizer’s Centers for Therapeutic Innovation (CTI) Call for Proposals (CFP) to share details about our areas of interest and the timeline for submission of non-confidential pre-proposals this round. CTI focuses on accessing cutting-edge science and innovative discoveries aligned with Pfizer’s current core research areas of Oncology, Inflammation & Immunology, Rare Diseases, and Internal Medicine.

Click here to learn more!

Share this article:

 

Last Updated: 5/10/21